title: Three cases of herpes zoster radiculitis in MS patients treated with natalizumab.
abstract: Natalizumab was the first FDA-approved monoclonal antibody for the treatment of multiple sclerosis (MS). We report on 3 natalizumab-treated patients who developed herpes zoster infections. In addition to progressive multifocal leukoencephelopathy, other opportunistic infections have been rarely reported during Natalizumab treatment. We believe that clinicians need heightened awareness of these infections in view of the risks of serious complications.
authors.affiliation: Nehme and Therese Tohme Multiple Sclerosis Center, Department of Neurology, American University of Beirut Medical Center, Beirut, Lebanon.
authors.forename: Bassem I
authors.initials: BI
authors.lastname: Yamout
authors.affiliation: Nehme and Therese Tohme Multiple Sclerosis Center, Department of Neurology, American University of Beirut Medical Center, Beirut, Lebanon.
authors.forename: Nuhad
authors.initials: N
authors.lastname: Abou Zeid
authors.affiliation: Nehme and Therese Tohme Multiple Sclerosis Center, Department of Neurology, American University of Beirut Medical Center, Beirut, Lebanon.
authors.forename: Ali J
authors.initials: AJ
authors.lastname: Taha
authors.affiliation: Nehme and Therese Tohme Multiple Sclerosis Center, Department of Neurology, American University of Beirut Medical Center, Beirut, Lebanon.
authors.forename: Maya M
authors.initials: MM
authors.lastname: Zeineddine
authors.affiliation: Nehme and Therese Tohme Multiple Sclerosis Center, Department of Neurology, American University of Beirut Medical Center, Beirut, Lebanon. Electronic address: sk88@aub.edu.lb.
authors.forename: Samia J
authors.initials: SJ
authors.lastname: Khoury
mesh_terms: D005260:Female; D006562:Herpes Zoster / Q000150:complications*; D006801:Humans; D007155:Immunologic Factors / Q000009:adverse effects* / Q000627:therapeutic use; D008875:Middle Aged; D020529:Multiple Sclerosis, Relapsing-Remitting / Q000150:complications* / Q000188:drug therapy*; D000069442:Natalizumab / Q000009:adverse effects* / Q000627:therapeutic use; D055815:Young Adult
chemical_list: D007155:Immunologic Factors; D000069442:Natalizumab
keywords: Herpes zoster; Lebanon; Middle East; Multiple sclerosis; Natalizumab